Income Per Common Share (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended																12 Months Ended
	Dec. 31, 2016	[1]	Sep. 30, 2016	[1]	Jun. 30, 2016	[1]	Mar. 31, 2016	[1]	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2016		Dec. 31, 2015		Dec. 31, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Net income	$ 2,897		$ 2,993		$ 2,347		$ 2,541		$ 2,636	$ 2,145	$ (502)	$ (274)	$ 1,776	$ 2,326	$ 2,161	$ 1,059	$ 10,778		$ 4,005		$ 7,322
Net income (loss) allocated to participating securities																	(208)		(87)		(161)
Net income allocated to common shareholders																	$ 10,570		$ 3,918		$ 7,161
Basic weighted-average common shares outstanding																	31,855,000		27,744,000		27,379,000
Basic income per common share																	$ 0.33		$ 0.14		$ 0.26
Net income (loss) allocated to participating securities, diluted																	$ (202)		$ (87)		$ (158)
Net income allocated to common shareholders, diluted																	$ 10,576		$ 3,918		$ 7,164
Effect of dilutive stock options and awards																	967,000		798,000		934,000
Diluted weighted-average common shares outstanding																	32,822,000		28,542,000		28,313,000
Diluted income per common share	$ 0.09		$ 0.09		$ 0.07		$ 0.08		$ 0.09	$ 0.07	$ (0.02)	$ (0.01)	$ 0.06	$ 0.08	$ 0.08	$ 0.04	$ 0.32	[2]	$ 0.14	[2]	$ 0.25	[2]
Stock Options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive securities excluded from computation of earnings per share																	1,000		710,000		335,000

[1] In January 2016 the Company completed its acquisition of On-X Life Technologies Holdings, Inc., which is being operated as a wholly owned subsidiary of CryoLife. In 2016 the Company also sold its HeRO Graft product line and its ProCol product line, and ceased sales of these products during 2016.

[2] The Company excluded stock options from the calculation of diluted weighted-average common shares outstanding if the per share value, including the sum of (i) the exercise price of the options and (ii) the amount of the compensation cost attributed to future services and not yet recognized, was greater than the average market price of the shares, because the inclusion of these stock options would be antidilutive to income per common share. Accordingly, stock options to purchase 1,000, 710,000, and 335,000 shares for the years ended December 31, 2016, 2015, and 2014, respectively, were excluded from the calculation of diluted weighted-average common shares outstanding.